27.28MMarket Cap-1437P/E (TTM)
0.700High0.670Low24.96KVolume0.695Open0.665Pre Close17.27KTurnover0.25%Turnover RatioLossP/E (Static)39.54MShares1.90052wk High-1.65P/B7.01MFloat Cap0.57052wk Low--Dividend TTM10.16MShs Float22.155Historical High--Div YieldTTM4.51%Amplitude0.570Historical Low0.691Avg Price1Lot Size
MiNK Therapeutics Stock Forum
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpo...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
CEO bought a lot
Gene therapies..hot cake for now and duti
ER May 11
No comment yet